Norspan (Buprenorphine)

Buprenorphine, a partial mu‑opioid receptor agonist, is indicated for several types of chronic pain.

• Chronic severe pain: provides continuous analgesia for patients with persistent severe pain not adequately controlled by other opioids.
• Cancer pain: offers sustained pain relief for patients with malignant disease experiencing moderate to severe pain.
• Non‑cancer chronic pain: reduces pain intensity in conditions such as osteoarthritis or neuropathic pain when other treatments are insufficient.

• Buprenorphine binds with high affinity to the μ‑opioid receptor, acting as a partial agonist that activates the receptor to a limited extent, producing analgesia while limiting maximal respiratory depression. It also antagonizes the κ‑opioid receptor, contributing to its analgesic profile and reducing dysphoria. The transdermal patch delivers a steady dose through the skin, maintaining stable plasma concentrations over several days.

Transdermal buprenorphine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Application site erythema: redness or irritation at the patch site.
• Pruritus: itching around the patch area.
• Nausea: feeling of sickness or urge to vomit.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing, especially with other depressants.
• Hypotension: unusually low blood pressure.
• Seizures: rare occurrence of convulsive episodes.

When prescribing Norspan, several safety considerations should be observed.

• Patient selection: assess opioid tolerance and history of substance misuse before initiating therapy.
• Concomitant CNS depressants: avoid or closely monitor use with benzodiazepines, alcohol, or other sedatives.
• Respiratory function: monitor for signs of respiratory depression, particularly during dose escalation.
• Skin integrity: inspect the application site regularly for irritation or allergic reaction.
• Cardiovascular risk: use caution in patients with severe cardiac disease or hypotension.
• Store at room temperature: keep patches below 25 °C in the original pouch, protect from moisture and direct sunlight.

Buprenorphine may interact with other medicines, altering its effect or increasing risk of adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: drugs such as rifampicin can markedly reduce buprenorphine plasma levels.
• Combined opioid agonists: using full opioid agonists can increase risk of respiratory depression.

Moderate Interactions (Monitor Closely)

• Benzodiazepines: concurrent use may enhance sedation and respiratory depression.
• Antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome.
• CNS depressants: alcohol or antihistamines may potentiate sedative effects.